The clinical diagnosis of major depressive disorder has long served as a catch-all category for a deeply heterogeneous group of…
Read More
What if psilocybin works about as well for depression as an SSRI?
The burgeoning optimism surrounding classic psychedelics as a transformative treatment for depression is beginning to face a crucial reality check.…
Read More
Existing Chronic Constipation Drug Shows Potential in Treating Cognitive Impairment and Brain Fog Associated with Depression
The medical community has long recognized that the journey to recovery from major depressive disorder (MDD) is rarely a linear…
Read More
Johnson & Johnson’s Spravato Remission Data Takes Center Stage in Push for Treatment-Resistant Depression Growth
A recent poster presentation at Psych Congress Elevate by Johnson & Johnson has placed esketamine nasal spray, marketed as Spravato,…
Read More
What if psilocybin works about as well for depression as an SSRI?
The burgeoning optimism surrounding classic psychedelics as revolutionary treatments for depression may need a recalibration, as emerging data suggests their…
Read More
Existing Chronic Constipation Medication Demonstrates Significant Potential to Alleviate Lingering Cognitive Deficits in Post-Depression Recovery
While the clinical treatment of major depressive disorder has historically focused on stabilizing mood and emotional regulation, a significant portion…
Read More
J&J Positions Spravato Remission Data at Forefront of Treatment-Resistant Depression Growth Strategy
Johnson & Johnson (J&J) is intensifying its marketing efforts for Spravato (esketamine) by spotlighting compelling remission rate data for treatment-resistant…
Read More
What if psilocybin works about as well for depression as an SSRI?
Emerging data from recent studies and meta-analyses suggest that the highly anticipated efficacy of classic psychedelics, particularly psilocybin, in treating…
Read More
GLP-1R Weight Loss Drugs May Alleviate Depression Through Gut Microbiome-Endocannabinoid-Brain Axis
Emerging evidence has consistently suggested that glucagon-like peptide-1 receptor (GLP-1R) weight loss drugs, initially developed for metabolic conditions, may offer…
Read More
J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push
More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis in 1962 while diligently searching for a safer…
Read More
